As Pharmacy Technician Day approaches, the CEO of the Pharmacy Technician Certification Board argues that real recognition means career ladders, consistent scope regulations, and investment in certification.
|Articles|May 18, 2019
- May 2019 Skin & Eye Health
- Volume 85
- Issue 5
Painful Scripts (May 2019)
Can you read these prescriptions?
Advertisement
Rx 1: MS Contin 15 mg; dosing: 1 tablet by mouth every 12 hours; quantity: #60 (sixty)
Rx 2: Aldactone 25 mg
Submit Your Illegible Prescriptions
Send in your eye-straining, baffling prescriptions—now via email, fax, and regular mail! Submissions must include a clean photocopy or scanned image of the Rx; your institution’s name and location; your name and title; the correct name of the drug(s), strength, and dosing requirements; and your phone number. You can email scanned Rxs to cmollison@pharmacytimes.com, fax them to 609- 257-0701, or mail them to Painful Scripts, Pharmacy Times®, 2 Clarke Drive, Suite 100, Cranbury, NJ 08512.
Articles in this issue
over 7 years ago
Case Studies (May 2019)over 7 years ago
Vaccines: There Is an App for Thatover 7 years ago
Be Aware of Corresponding Responsibilityover 7 years ago
OTC Case Studies: Skin and Eye Healthover 7 years ago
Generic Products (May 2019)over 7 years ago
Oral Contraceptives Are Susceptible to Several Interactionsover 7 years ago
Medication Synchronization Laws Can Improve Adherenceover 7 years ago
What Factors Are Contributing to Drug Shortages?over 7 years ago
Rx Products (May 2019)Advertisement
Related to this article
William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1C by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge
2
Why Patients Fear Statins Will Affect Their Memory
3
Orforglipron Shows CV Safety vs Insulin Glargine in ACHIEVE-4
4
Suzetrigine After Knee Replacement: Are Fewer Opioid Prescriptions Enough?
5